ALBERTO SOLA LEYVA-rekin lankidetzan egindako argitalpenak (3)

2022

  1. Anticancer Activity of the Choline Kinase Inhibitor PL48 Is Due to Selective Disruption of Choline Metabolism and Transport Systems in Cancer Cell Lines

    Pharmaceutics, Vol. 14, Núm. 2

2019

  1. Biomimetic magnetic nanocarriers drive choline kinase alpha inhibitor inside cancer cells for combined chemo-hyperthermia therapy

    Pharmaceutics, Vol. 11, Núm. 8

  2. Choline kinase inhibitors EB-3D and EB-3P interferes with lipid homeostasis in HepG2 cells

    Scientific Reports, Vol. 9, Núm. 1